{"@type":"Dataset","go_id":["https://identifiers.org/GO:0009062","https://identifiers.org/GO:0006544","https://identifiers.org/GO:0006750"],"go_kw":["fatty acid degradation","glycine metabolism","glutathione formation"],"integmet_study":"MTBLS5005","mesh_chemical_id":["https://identifiers.org/mesh:C000591538","https://identifiers.org/mesh:D005998","https://identifiers.org/mesh:D005227","https://identifiers.org/mesh:D005978","https://identifiers.org/mesh:D001647"],"mesh_chemical_pubtator_kw":["Gly-Gly-Leu","glycine","fatty acid","glutathione","bile acid"],"mesh_disease_id":["https://identifiers.org/mesh:D065626","https://identifiers.org/mesh:D005234","https://identifiers.org/mesh:D005355"],"mesh_disease_pubtator_kw":["nonalcoholic steatohepatitis","hepatic steatosis","steatohepatitis","NASH","fibrosis","Nonalcoholic steatohepatitis"],"ncbi_taxonomy_id":["https://identifiers.org/taxonomy:9606","https://identifiers.org/taxonomy:10090"],"ncbi_taxonomy_pubtator_kw":["human","mice"],"source_id":"https://identifiers.org/metabolights:MTBLS5005","study_findings":"DT-109 reverses hepatic steatosis and prevents fibrosis progression by modulating metabolism.","study_observation":"Effects of DT-109 on steatohepatitis and fibrosis in nonhuman primates.","study_summary":"DT-109 ameliorates NASH in nonhuman primates.","study_title_original":"DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates"}